PMID- 21440523
OWN - NLM
STAT- MEDLINE
DCOM- 20111014
LR  - 20221207
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 5
IP  - 2
DP  - 2011 Jul
TI  - Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes 
      mellitus in a largely primary care-based setting in Sweden.
PG  - 89-94
LID - 10.1016/j.pcd.2011.02.003 [doi]
AB  - AIMS: Despite a wealth of clinical trial data supporting use of the premixed 
      insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 
      2 diabetes mellitus (T2DM), there is limited documentation of its use in primary 
      care-based clinical practice. METHODS: An observational study investigating the 
      safety and efficacy of BIAsp 30 in routine clinical practice was conducted. 
      Patients were followed up 3 and 6 months after initiating insulin treatment. 
      Safety and efficacy measures were documented. RESULTS: During the course of the 
      study, 1154 patients were included (age range 20-95 years), of whom 89% completed 
      the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and 
      had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total 
      hypoglycaemia at completion of the study was 4.1 events per patient year. Major 
      hypoglycaemic events were rare (two in total). CONCLUSIONS: BIAsp 30 was 
      initiated safely and effectively in insulin-naive patients with T2DM. The safety 
      and efficacy profile observed in clinical trials was confirmed in this largely 
      primary care-based setting in Sweden.
CI  - Copyright (c) 2011 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Berntorp, Kerstin
AU  - Berntorp K
AD  - Department of Clinical Sciences, Lund University, Malmo, Sweden.
FAU - Haglund, Mattias
AU  - Haglund M
FAU - Larsen, Sara
AU  - Larsen S
FAU - Petruckevitch, Ann
AU  - Petruckevitch A
FAU - Landin-Olsson, Mona
AU  - Landin-Olsson M
CN  - Swedish BIAsp Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110326
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Biomarkers)
RN  - 0 (Biphasic Insulins)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 0 (insulin aspart, insulin aspart protamine drug combination 30:70)
RN  - 53027-39-7 (Insulin, Isophane)
RN  - D933668QVX (Insulin Aspart)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Biphasic Insulins
MH  - Blood Glucose/drug effects
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Health Services Research
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Insulin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Insulin Aspart
MH  - Insulin, Isophane
MH  - Male
MH  - Middle Aged
MH  - *Primary Health Care
MH  - Prospective Studies
MH  - Sweden/epidemiology
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/03/29 06:00
MHDA- 2011/10/15 06:00
CRDT- 2011/03/29 06:00
PHST- 2010/10/01 00:00 [received]
PHST- 2011/01/24 00:00 [revised]
PHST- 2011/02/16 00:00 [accepted]
PHST- 2011/03/29 06:00 [entrez]
PHST- 2011/03/29 06:00 [pubmed]
PHST- 2011/10/15 06:00 [medline]
AID - S1751-9918(11)00020-9 [pii]
AID - 10.1016/j.pcd.2011.02.003 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2011 Jul;5(2):89-94. doi: 10.1016/j.pcd.2011.02.003. Epub 
      2011 Mar 26.